Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Teva Profits Hit $761M

By R&D Editors | May 11, 2011

NEW YORK (AP) – Teva Pharmaceutical Industries Ltd. said its profit rose 7 percent in the first quarter as its latest acquisitions boosted its sales overseas.

The world’s largest maker of generic drugs said its profit grew to $761 million, or 84 cents per share, from $714 million, or 79 cents per share, a year ago. Excluding one-time items, Teva said it earned $1.04 per share. Revenue increased 12 percent to $4.08 billion.

Analysts expected a profit of $1.04 per share and $4.28 billion in revenue, according to estimates compiled by FactSet.

Revenue from the company’s multiple sclerosis drug Copaxone grew 14 percent to $907 million, and revenue from its Parkinson’s disease drug Azilect grew 16 percent to $90 million. Revenue from the company’s respiratory business grew 19 percent and its women’s health revenue rose 30 percent.

The Israeli company has made a series of deals that expanded its business outside the U.S., which is still its largest market but now only brings in about half of its revenue.

In August, Teva acquired German drugmaker Ratiopharm, and Teva said its European sales rose 66 percent to $1.34 billion. Its North American revenue fell 11 percent to $2.06 billion because of reduced generic drug sales.

Revenue in Eastern Europe, the Middle East, Africa, Latin America and Asia rose a combined 26 percent to $672 million. That business got a boost after Teva bought drugmaker Corporacion Infarmasa of Peru.

Earlier this month, Teva agreed to buy Cephalon Inc., which makes the sleep disorder drug Provigil and the pain drug Fentora, in a deal valued at $6.8 billion or $81.50 per share. The deal is expected to close during the third quarter.

Teva maintained its annual profit forecast of $4.90 to $5.25 per share and $18.5 billion to $19 billion in revenue. Analysts are expecting net income of $5.07 per share and revenue of $18.73 billion on average.

Date: May 11, 2011
Source: Associated Press

Related Articles Read More >

2025 R&D layoffs tracker hits 132,075 as Amazon CEO signals AI will cut more jobs
Probiotics power a bioresorbable battery that can run from 4 to 100+ minutes
Health-related innovation in Morocco highlighted by resident inventor patenting activity
ARPA-H funds $29M Ginkgo-led project to reshore pharma supply chains using wheat germ tech
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE